Clinical trial · Observational
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
NCT01240161CI-TRIAL-00029314completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High Grade Glioma | High-Grade Glioma, NOS | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with high grade gliomas
- description
- All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
- interventionNames
- Drug: FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT
Primary outcomes (2)
- measure
- Overall Survival
- timeFrame
- 7 months
- measure
- Progression free Survival
- timeFrame
- 7 months
- description
- MRI and clinical criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT * Anticipated survival ≥6 months * Able to give informed consent * Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia * Male or Female Exclusion Criteria: * Prior radiation therapy and chemotherapy to the brain * Active intracranial infection or nonglial brain mass. * Recent large intracranial hemorrhage (\<1 month) * Expected survival \<6 months * Pregnant or nursing * Renal failure * Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.
References
Publications (0)
Data not yet available
No reference posted for this study.